Category - NVS

AGE AKAO AMRN ATHX Avisol Capital Partners BBC BBH BBP BioSci Capital Partners BTX Clover Biotech Research CNCR CYDY DNLI Early Retiree ESRX EXEL FBT FENC Games GBT GSK HQL IBB Jérôme Verony Jonathan Faison LABD LABU MRNS NERV NKTR NVCR NVS ONeil Trader PBE PRTK PTGX RGNX SA Marketplace SGYP Slingshot Insights SUPN Terry Chrisomalis UBIO Wall Street Titan XBI ZBIO ZGNX

Keeping Focused Amidst The Biotech Bear – AgeX Therapeutics Inc (NYSEMKT:AGE)

2018 appears to be ending on a nasty notice within the markets. December is setting the incorrect type of data, and This fall has been a bumpy one generally...

AGN AKCA ALNY ALXN AMGN AMRN ARGX ARNA ARRY ATRA AZN BCRX BIIB BMY CDXS CELG CFA CORT CVS DCPH DNLI ELY ESPR ESRX EXEL FATE Games GBT GSK GWPH HCM IBB ICPT INCY JNJ LABD LABU MRK MRNA MRTX NKTR NVO NVS PFE PRQR REGN SPY Tarun Chandra TSRO VCEL VNDA VRTX XBI XLV

Biotech Bonanza: 2019 Outlook On An Uphill Battle

Contents 1 Biotech Pulse 2 Regulatory Panorama To Stay Comparable However Noisier 3 Biotech Pipeline Stays Wealthy With Potential 4 Mergers & Acquisitions...

AGCO ANAT AVT AXP AZO BAX BIDU BK BRK.A BRK.B CKX CMCSA CNHI COP CSCO CTWS DEO DVN EMR Games GOOG GOOGL GSK HAL HSBC JNJ John Vincent KOF MA MMM MRC MRK NSRGY NVS NWLI PSX RDS.A RDS.B RHHVF SAFRF SAFRY SHEN TBCUX TBGVX TBHDX TMK TOT TWEBX UL UN UNF UNP USB VZ WFC WPP

Tracking Tweedy Browne Portfolio – Q3 2018 Update

This text is a part of a collection that gives an ongoing evaluation of the modifications made to Tweedy Browne’s 13F portfolio on a quarterly foundation...